Navigation Links
InspireMD Closes $25 Million Underwritten Public Offering
Date:4/16/2013

TEL AVIV, Israel, April 16, 2013 /PRNewswire/ --

InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR) announced the closing of an underwritten public offering of 12.5 million shares of its common stock at a price to the public of $2.00 per share.  The Company received net proceeds of approximately $22.6 million, after deducting underwriting discounts and commissions and other offering-related costs.  InspireMD granted the underwriters a 30-day option to purchase up to an additional 1.875 million shares to cover over-allotments, if any.

The Company intends to use a portion of the proceeds from the offering to assist in retiring its convertible debentures, to support the worldwide commercialization of the MGuard[TM] Coronary and Carotid Embolic Protection Stents (EPS), to pursue FDA approval in the United States, and for general corporate purposes. Following this offering, the Company will not have any indebtedness for borrowed money outstanding.

Cowen and Company, LLC was sole book runner and JMP Securities acted as co-lead manager.  

The offering of these securities were made only by means of a prospectus. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission (SEC). The registration statement may be accessed through the SEC's website at http://www.sec.gov.

A prospectus relating to these securities may be obtained from Cowen and Company, LLC (c/o Broadridge Financial Services) at 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by calling (631) 274-2806.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation
'/>"/>

SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InspireMD Announces First Quarter 2012 Financial Results
2. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
3. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
4. InspireMD to Present at Harvard Investors Group on June 27 in New York
5. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
6. InspireMD Reports Results For Period Ending Sept. 30, 2012
7. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
8. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
9. InspireMD Reports Results for Period Ended Dec. 31, 2012
10. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
11. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... WOODCLIFF LAKE, N.J. and SAN DIEGO ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today that ... Phase 3 trials of lorcaserin entitled, "Early Weight Loss While ... 52 Weight-Loss Outcomes," was recently published in the online issue ... The Obesity Society. The objective of these analyses was to ...
(Date:7/30/2014)... NEW YORK , July 30, 2014 /PRNewswire/ ... new products for oncology supportive care, announced that its ... been featured in an article on OncLive.com titled, "Study ... and Neck Cancers."  Dr. Steve Sonis , a ... growing demand seen in the oncology community for evidence-based ...
(Date:7/30/2014)... July 30, 2014 /PRNewswire-iReach/ -- This is a ... Chinese Heparin sodium (CAS 9041-08-1) & calcium (CAS ... information of Heparin sodium (CAS 9041-08-1) & calcium ... technology. The report then explores global and China,s ... calcium (CAS 37270-89-6) listing their product specification, capacity, ...
Breaking Medicine Technology:Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5
... number of costs associated with nonprescription drug manufacturing and ... half years. Certain material costs for plastic bottles and ... time, increasing packaging expenses. Advertising and marketing expenses continue ... of marketers reduced advertising costs in 2009, and in ...
... ERES ) announced today that it will release ... 4, 2010, after the market closes. After the release, the ... that day. For the conference call, interested ... or 1-412-858-4600 when calling internationally. There will be a playback ...
Cached Medicine Technology:Nonprescription Drugs Cost Structures Fluctuate with Increased Cost of Goods, According to Kline 2Nonprescription Drugs Cost Structures Fluctuate with Increased Cost of Goods, According to Kline 3ERT to Announce Third Quarter 2010 Results on November 4, 2010 2
(Date:7/31/2014)... July 31, 2014 Eden Lew ... ‘Chuck’ Forman - Crawford Technologies" Scholarship through ... was created to honor the contributions Chuck Forman ... his industry. Chuck lost his battle with cancer ... outstanding, and we are thrilled to see her ...
(Date:7/31/2014)... Chicago, IL (PRWEB) July 31, 2014 ... Brickner; “no, not the summer’s hottest metal bands ~ ... Homeostatic Cannabinoid Science ~ Publius’ July Roundup, new ... articles are noted on homeostasis and the cannabinoid system ... modulation of our health and wellness: three directly on ...
(Date:7/31/2014)... 2014 Daily Gossip reveals in its review ... discover some breakthrough weight loss tips. , The author ... recommendations are very simple to implement. Users don’t have to ... no need to start counting calories. , The Flat ... fact created a 12 weeks weight loss program to help ...
(Date:7/31/2014)... 2014 In its latest blog post, ... that having family close by during a stay in rehab ... process is successful, is looking at 11 drug addiction facts ... be. , “While some kids learn a little ... class, the coverage is typically woefully inadequate,” commented Best Drug ...
(Date:7/31/2014)... 2014 Dolce Vite Chocolatto®, world's ... in New York's favorite specialty coffee roaster and DUMBO ... for their commitment to Fair Trade coffee and was ... the new sensation from Italy as the world’s best ... highly popular Italian dessert descended from European Royalty. Prepared ...
Breaking Medicine News(10 mins):Health News:Eden Lew Recipient of 2014 EDSF Scholarship Honoring Chuck Forman 2Health News:Eden Lew Recipient of 2014 EDSF Scholarship Honoring Chuck Forman 3Health News:Homeostatic Cannabinoid Science ~ Publius’ July Roundup on the Bryan William Brickner Blog 2Health News:New Best Drug Rehabilitation Blog Posts Looks at 11 Drug Addiction Facts they Don’t Teach in School 2Health News:Dolce Vite Chocolatto® - World's Best Thick Dark Italian Hot Chocolate Now Available at NYC's Favorite Cafe Brooklyn Roasting Company 2
... and 24 are smokers, and most say they keep lighting up ... have found that when it comes to quitting, a little bit ... plan in helping women not only keep off the weight, but ... to keep their weight down and for body image reasons, and ...
... in breakthrough creativity in the DTC category, Med Ad ... Wellness as the winner of both the Most Creative ... commenting on the awards, Saatchi & Saatchi Wellness Managing ... advertising icon Helayne Spivak and I knew we needed ...
... diabetes therapy, positively influencing compliance and persistency; electronic ... of dispensing ACCU-CHEK(R) test strips.INDIANAPOLIS, April 24 ... eVoucherRx(TM) pilot program in Florida, designed to make ... their co-pay savings on ACCU-CHEK test strips. The ...
... lowers patients, financial responsibility for their diabetes therapy, ... works in real time at point of dispensing ... today the launch of its new eVoucherRx(TM) pilot ... for patients with diabetes to receive their co-pay ...
... continuing to rise even though the number of cases ... reveals. , The report entitled Cancer incidence, mortality, treatment ... 1994-2004, was compiled by the Northern Ireland Cancer Registry ... Registry (NCRI) of Ireland, in Cork. , This is ...
... help look out for seniors, welfareDETROIT, April 24 ... the lookout and help identify potentially vulnerable elderly customers ... more necessary as Michigan,s economy continues to tumble."Times are ... to do our part to help ensure people don,t ...
Cached Medicine News:Health News:Mind over muscle 2Health News:Saatchi & Saatchi Wellness Wins Creative Awards Honored At 20th Annual Manny Awards 2Health News:Roche Announces New Co-pay Program in Florida that Makes It Easier for Patients with Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips 2Health News:Roche Announces New Co-pay Program in Florida that Makes It Easier for Patients with Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips 3Health News:Roche Announces New Co-Pay Program in California That Makes it Easier for Patients With Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips 2Health News:Roche Announces New Co-Pay Program in California That Makes it Easier for Patients With Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips 3Health News:Survival rates for cancer rise across Ireland 2Health News:Survival rates for cancer rise across Ireland 3Health News:DTE Energy Asks Employees to Help Safeguard Customers 2
... The SR™ Hand Implant System utilizes ... and knee joint replacements. The SR™ ... available in other prostheses including minimal bone ... eroded cartilaginous articular surfaces, retention and/or repositioning ...
For use in implant resection arthroplasty of the trapeziometacarpal joint in cases of rheumatoid, degenerative or post-traumatic arthritis....
The efficient choice for small joint replacement technology -- the Ascension Silicone MCP features a similar design to our PyroCarbon MCP and utilizes the same instrumentation for intra-operative fle...
... Hand Implant System utilizes the same proven ... replacements. The SR™ Hand Implant System ... prostheses including minimal bone resection, surface replacement ... surfaces, retention and/or repositioning of the ligamentous ...
Medicine Products: